Pharmacokinetic evaluation of XXXX for pemphigus.

@entity1 @entity3442 @entity7271 @entity2098 @entity27705 @entity618 @entity230 @entity792 @entity288
INTRODUCTION: @entity7271 is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, @entity27705 . Before the advent of @entity288 , therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to     10%, but long-term use of @entity230 can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the @entity1 's cumulative exposure to systemic @entity288 . Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have been described, but these therapies are not without potentially serious complications. Despite the range of treatment options, a proportion of @entity1 do not achieve remission, while others show an initial treatment response but remain poorly controlled. The recent availability of @entity618 ( @entity2098 ), originally developed for preventing allograft rejection, appears to be effective in @entity792 in combination with systemic corticosteroid or as a monotherapy. AREAS COVERED: This review aims to provide an extensive overview of the literature on the clinical pharmacokinetics of @entity2098 in pemphigus treatment and a brief summary of current pharmacodynamic information. After completing this learning activity, readers should be able to summarize the pharmacology of @entity2098 as an immunosuppressant; recognize its potential role in the treatment of pemphigus, including general dosing guidelines and laboratory monitoring schedules, use in @entity1 populations and potential adverse effects; and identify future considerations and developing areas of research regarding the use of @entity3442 in the treatment of @entity792 . EXPERT OPINION: Current morbidity of pemphigus is largely iatrogenic, caused by side effects of the long-term, high-dose corticosteroid therapy that is necessary to sustain disease control. @entity2098 demonstrates complex pharmacokinetics and displays large between-subject pharmacokinetic variability. Experience with @entity2098 has demonstrated long-term safety and tolerability in the treatment of pemphigus.
